You just read:

U.S. FDA Grants Priority Review to Boehringer Ingelheim's Afatinib NDA for EGFR Mutation-Positive Advanced NSCLC

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Jan 15, 2013, 08:00 ET